Year: 2016
Type: review
Abstract: Cerebrospinal fluid (CSF) is enriched in brain-derived components and represents an accessible and appealing means of interrogating the CNS milieu to study neurodegenerative diseases and identify biomarkers to facilitate the development of novel therapeutics. Many such CSF biomarkers have been proposed for Huntington's disease (HD) but none has been validated for clinical trial use. Across many studies proposing dozens of biomarker candidates, there is a notable lack of statistical power, consistency, rigor and validation. Here we review proposed CSF biomarkers including neurotransmitters, transglutaminase activity, kynurenine pathway metabolites, oxidative stress markers, inflammatory markers, neuroendocrine markers, protein markers of neuronal death, proteomic approaches and mutant huntingtin protein itself. We reflect on the need for large-scale, standardized CSF collections with detailed phenotypic data to validate and qualify much-needed CSF biomarkers for clinical trial use in HD.
Source: Journal of Huntington s Disease
DOI: 10.3233/jhd-160196
Authors: Lauren M. Byrne, Edward J. Wild
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: Huntington's disease, cerebrospinal fluid biomarkers, biomarker validation, neurotransmitters, transglutaminase activity, kynurenine pathway metabolites, oxidative stress biomarkers, inflammatory markers, neuroendocrine markers, proteomics, mutant huntingtin, neurodegeneration, clinical trial biomarkers
Open Access status: bronze
OpenAlex ID: W2317944362
